Role of Pharmacokinetic Effects in the Potentiation of Morphine Analgesia by L-Type Calcium Channel Blockers in Mice

Journal of Pharmacological Sciences

Volumn 94, Issue 3, 2004, Pages 240-245

  Shimizu, Norifumi ^a   Kishioka, Shiroh ^a   Maeda, Takehiko ^a   Fukazawa, Yohji ^a   Yamamoto, Chizuko ^a   Ozaki, Masanobu ^b   Yamamoto, Hiroyuki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Diltiazem; Morphine analgesia; Nimodipine; Pharmacokinetics; Verapamil

Indexed keywords

BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; MORPHINE; NIMODIPINE; PHENYLALKYLAMINE; VERAPAMIL;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENTIATION; HEMOCONCENTRATION; INJECTION; MALE; MOUSE; NONHUMAN;

EID: 1842783152     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.94.240     Document Type: Article

References (36)

1. Contreras E, Tamayo L, Amigo M. Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance. Eur J Pharmacol. 1988;148:463-466.
2. Antkiewicz-Michaluk L, Michaluk J, Romanska I, Vetulani J. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology (Berl). 1993;111:457-464.
3. Benedek G, Szikszay M. Potentiation of thermoregulatory and analgesic effects of morphine by calcium antagonists. Pharmacol Res Commun. 1984;16:1009-1018.
4. Omote K, Sonoda H, Kawamata M, Iwasaki H, Namiki A. Potentiation of antinociceptive effects of morphine by calciumchannel blockers at the level of the spinal cord. Anesthesiology. 1993;79:746-752.
5. Wei ZY, Karim F, Roerig SC. Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels. J Pharmacol Exp Ther. 1996;278:1392-1407.
6. Dogrul A, Yesilyurt O, Isimer A, Guzeldemir ME. L-type and T-type calcium channel blockade potentiate the analgesic effects of morphine and selective mu opioid agonist, but not to selective delta and kappa agonist at the level of the spinal cord in mice. Pain. 2001;93:61-68.
7. Del Pozo E, Ruiz-Garcia C, Baeyens JM. Analgesic effects of diltiazem and verapamil after central and peripheral administration in the hot-plate test. Gen Pharmacol. 1990;21:681-685.
8. Murray M, Butler AM. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther. 1996;279:1447-1452.
9. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389-430.
10. Liu XQ, Ren YL, Qian ZY, Wang GJ. Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000;21:690-694.
11. Liu Z, Mortimer O, Smith CA, Wolf CR, Rane A. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol. 1995;39:77-80.
12. Caraco Y, Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos. 1996;24:761-764.
13. Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993;268:16059-16064.
14. 2+-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp Clin Res. 1994;20:13-18.
15. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos. 1999;27:827-834.
16. Takagi H, Inukai T, Nakama M. A modification of Haffner's method for testing analgesics. Jpn J Pharmacol. 1966;16:287-294.
17. Tallarida RJ, Murray RB. Manual of Pharmacological Calculation with Computer Programs. New York: Springer-Verlatg Press; 1987.
18. Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronidation of morphine. J Pharmacobiodyn. 1991;14:187-193.
19. Aasmundstad TA, Ripel A, Bodd E, Bjomeboe A, Morland J. Different biotransformation of morphine in isolated liver cells from guinea pig and rat. Biochem Pharmacol. 1993;46:961-968.
20. Della Puppa A, Ford-Rice F, Snyder FR, Cone E, London ED. Time course of verapamil interaction with morphine effects on physiological parameters in rats. J Pharm Pharmacol. 1989;41:617-623.
21. Thievant P, Baranes J, Le Hegarat M, Clostre F, DeFeudis FV. Effects of diltiazem on renovascular-hypertensive and on normotensive rats. Gen Pharmacol. 1982;13:165-168.
22. Young WL, Chien S. Effect of nimodipine on cerebral blood flow and metabolism in rats during hyperventilation. Stroke. 1989;20:275-280.
23. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695-698.
24. Zong J, Pollack GM. Morphine antinociception is enhanced in mdr1 a gene-deficient mice. Pharm Res. 2000;17:749-753.
25. Cistemino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res. 2001;18:183-190.
26. Maekawa K, Minami M, Yabuuchi K, et al. In situ hybridization study of mu- and kappa-opioid receptor mRNAs in the rat spinal cord and dorsal root ganglia. Neurosci Lett. 1994;168:97-100.
27. Hassan AH, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience. 1993;55:185-195.
28. Coggeshall RE, Zhou S, Carlton SM. Opioid receptors on peripheral sensory axons. Brain Res. 1997;764:126-132.
29. Joris JL, Dubner R, Hargreaves KM. Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation? Anesth Analg. 1987;66:1277-1281.
30. Barber A, Gottschlich R. Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. Med Res Rev. 1992;12:525-562.
31. Junien JL, Wettstein JG. Role of opioids in peripheral analgesia. Life Sci. 1992;51:2009-2018.
32. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995;332:1685-1690.
33. Kayser V, Lee SH, Guilbaud G. Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy. Neuroscience. 1995;64:537-545.
34. Kolesnikov YA, Jain S, Wilson R, Pasternak GW. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J Pharmacol Exp Ther. 1996;279:502-506.
35. Tokuyama S, Inoue M, Fuchigami T, Ueda H. Lack of tolerance in peripheral opioid analgesia in mice. Life Sci. 1998;62:1677-1681.
36. Shannon HE, Lutz EA. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology. 2002;42:253-261.